Scientific Advice is one of the few moments in early development where a biotech can test its assumptions with regulators before those assumptions become timelines, contracts, and irreversible design choices. For lean teams, that is an opportunity to confirm what evidence regulators will expect, where the risks sit, and which trade-offs are acceptable. EMA frames Scientific Advice exactly in those terms. It helps developers generate robust evidence on benefits and risks and supports timely, sound development.
Scientific Advice is where strategy is tested in practice. Done well, it reduces rework before CTA preparation and helps you avoid last-minute complications when you are trying to move into first-in-human, provided the advice is requested early enough to leave time for briefing book preparation and for implementing feedback before submission work starts.
Start with decisions, not questions
The strongest Scientific Advice packages are built around a small set of high-impact decisions your team must make as the development program moves forward. For early stage biotechs, those decisions usually cluster into four areas.
- Regulatory pathway and sequencing. Centralized vs national routes where relevant, planned interactions, and what you need to show at each milestone. This is also a practical point when deciding where to seek advice. In some situations, national competent authorities may offer formats that enable more direct dialogue, including face-to-face meetings, which can influence how teams plan preparation and timelines compared with an EU-level procedure.
- Clinical strategy. Target population, endpoints, trial design choices, and feasibility.
- CMC and Quality Readiness. Manufacturing model, control strategy direction, comparability planning, and what “CTA-ready” means for your product.
- Evidence strategy. How nonclinical and early clinical data will support the next step.
Once the decisions are clear, questions become easier to write, and the advice becomes easier to use.
Structure Questions for Actionable Regulatory Advice
Many startups struggle to get value from Scientific Advice because their questions are framed too broadly or too generically. When questions are vague, regulators can only respond at a high level, which limits their practical usefulness.
EMA guidance makes it clear that Scientific Advice is intended to support concrete development decisions, not to validate an entire program. The most effective questions are therefore structured around real choices and clearly articulated risks. They describe the current proposal, explain why it has been selected, and highlight the uncertainties the team is trying to manage.
When questions are framed in this way, regulators can focus their feedback on evidence requirements, alternative approaches, and risk mitigation strategies. This turns Scientific Advice into a tool for decision-making rather than a general discussion.
Treat Scientific Advice as an Integrated Development Exercise
For emerging biotechs, Scientific Advice often loses value when it is approached in silos, with clinical questions prepared separately from CMC considerations, quality topics postponed, and safety strategy discussed in isolation. The result is a fragmented submission that does not fully reflect how the development plan actually functions.
A practical way to ensure consistency is to begin the document with a concise overview of the development strategy, outlining what the product is, which indication is targeted, what the next milestone will be, and where the main uncertainties sit. Each question should then link clearly to one of these uncertainties, making it easier for regulators to provide focused feedback and for the company to translate that feedback into concrete actions.
Use the process to your advantage
Scientific Advice is a defined procedure with preparatory steps, validation, assessment, and clarification within the ongoing procedure. EMA’s applicant guidance helps teams understand what to include and how to structure the request. For startups unfamiliar with EMA Scientific Advice, the preparatory step is often critical. Although it adds time upfront, it allows feedback from EMA Validation to help refine scope and adjust questions so that the written responses from the CHMP are as useful and specific as possible.
Two operational moves help lean teams avoid waste:
- Nominate owners per topic and a single integrator. One person owns the clinical questions, one owns CMC and another takes care of safety. A dedicated team member integrates, manages version control, and ensures the narrative stays consistent.
- Establish early how regulatory input will be translated into operational decisions. Decide how you will convert advice into actions, what will trigger a change in plan, and how you will document the rationale for future submissions.
This avoids the common situation where advice arrives, the team agrees it is important, and then execution drifts because no one owns conversion.
How EMA SME Support Reduces the Barrier to Scientific Advice
EMA provides specific fee reductions and support mechanisms for companies that qualify as SMEs, with the explicit aim of encouraging earlier interaction with regulators. These incentives apply to Scientific Advice procedures and are designed to lower the financial barriers that often delay regulatory engagement in small organizations. Eligibility depends on meeting EMA’s SME criteria, and in practice it may require an EU establishment or an appropriate EU-based SME linkage, so it is important to confirm applicability early when planning timelines and budgets.
For many emerging biotechs, this significantly changes the cost-benefit balance. Scientific Advice becomes a viable investment earlier in development, at a point where regulatory input can still shape strategy, prevent unnecessary rework, and deliver the greatest long-term value.
Closing Remarks
Scientific Advice delivers the greatest value when it is used to accelerate critical development decisions, by clarifying priorities, reducing uncertainty, and aligning the overall program before significant resources are committed. Its impact does not depend on the number of questions submitted, but on their relevance and precision, ensuring they are directly connected to real development choices and supported by a consistent strategy across clinical, CMC, quality, and safety domains.
关于作者
PhD · Global Head Regulatory Affairs at QbD Group
Angeles has built her career at the crossroads of science and regulation. From academic research at CNB and CNIC to leadership roles in biotech and global consulting firms like Asphalion, Parexel, Pharmalex, and Scendea, she translates regulatory complexity into action. She has a strong track record of building and scaling teams, and is especially focused on the intersection of data, AI, and regulation to unlock faster healthcare innovation.
订阅生命科学领域的最新动态
专家观点直达您的收件箱——选择您的兴趣。
绝无垃圾邮件。随时取消订阅。
